Close
Close

Disease Target Specific Antibody Discovery Services by Premade Library

Screening Services Workflow Premade Libraries Cases Related Services Why Choose Us? Work with Us FAQ

Having successfully delivered leads for a wide array of novel and conventional targets, we combine our proven expertise with high-diversity premade libraries to accelerate your R&D. We don't believe in one-size-fits-all; instead, we optimize every discovery campaign to align with your target's unique profile, ensuring high-efficiency binding and superior developability across any disease area.

We'll Reply Within 24 Hours. Request a Quote

Your Partner in Novel Antibody Discovery: Expert Strategies for Every Disease Type

When facing compressed timelines and complex biological targets, Creative Biolabs provides a decisive advantage. We combine one of the industry's largest collections of premade human antibody libraries with a proven track record of unlocking novel and challenging disease targets. We believe every therapeutic target requires a bespoke approach; therefore, we don't just screen but also strategize. By integrating our deep understanding of disease biology with customized development roadmaps, we transform your specific clinical requirements into robust, high-affinity, and highly developable lead candidates ready for the next stage of innovation.

Covering a Wide Range of Targets

Fig.1 Anti-Disease-specific Target Antibody Discovery. (Creative Biolabs Authorized)

Anti-tumor-specific Target Antibody Discovery
Designed for the discovery of therapeutic antibodies against various cancer-associated antigens, including tumor-associated antigens (TAAs), neoantigens, and more.

Anti-infectious disease-specific Antibody Discovery

Anti-infectious disease-specific Antibody Discovery
Designed for the discovery of antibodies against specific targets related to infectious diseases, including viruses, bacteria, and fungi, focusing on pathogen-specific epitopes and immune evasion mechanisms.

Anti-inflammation disease-specific Antibody Discovery

Anti-inflammation disease-specific Antibody Discovery
Designed for the discovery of antibodies that target specific mediators and pathways involved in chronic inflammatory diseases, such as pro-inflammatory cytokines, receptors, and signaling pathways implicated in diseases like rheumatoid arthritis, inflammatory bowel disease (IBD), and more.

Anti-autoimmune disorder-specific Antibody Discovery

Anti-autoimmune disorder-specific Antibody Discovery
Designed for the discovery of antibodies that target specific autoantigens and immune dysregulation mechanisms involved in autoimmune diseases, such as lupus, multiple sclerosis (MS), type 1 diabetes, and more.

Anti-allograft rejection-specific Antibody Discovery

Anti-allograft rejection-specific Antibody Discovery
Designed for the discovery of antibodies that can modulate immune responses to prevent or treat allograft rejection in transplant medicine.

Ready to Begin? Get Your Personalized Quote

Workflow

  • Fig.2 Discovery Design & Antigen Strategy. (Creative Biolabs AI)
    Discovery Design & Antigen Strategy

    Target assessment; antigen format optimization; decoy/competitor planning

  • Fig.3 Biopanning & Enrichment. (Creative Biolabs AI)
    Biopanning & Enrichment

    Competitive and subtractive panning; increasing stringency

  • Fig.4 Single-Clone Screening & Specificity De-risking. (Creative Biolabs AI)
    Single-Clone Screening & Specificity De-risking

    High-throughput validation; early polyspecificity triage

  • Fig.5 Functional Selection & Epitope Strategy. (Creative Biolabs AI)
    Functional Selection & Epitope Strategy

    Cell-based functional assays; epitope binning

  • Fig.6 Sequence Analytics & Liability Filtering. (Creative Biolabs AI)
    Sequence Analytics & Liability Filtering

    NGS-driven clustering

  • Fig.7 Expression, IgG Conversion & Developability Panel. (Creative Biolabs AI)
    Expression, IgG Conversion & Developability Panel

    Mini-panel IgG expression; biophysics profiling

  • Fig.8 Reporting. (Creative Biolabs AI)
    Reporting

    Fully technical report; next-step options

Kick Off Your Screen. Request Pricing.

Ready-to-Screen Antibody Libraries

Our libraries are the cornerstone of our discovery engine, built on robust, developability-optimized frameworks.

Human Camel Llama Alpaca Humanized VHH
Antibody Library ID Display Technology Library Format Library Size
HuScL-6
☆Highly Recommended 		pIII-fusion, Phagemid Phage Display Naïve scFv 2.1×1011
HuScL-3S pIII-fusion, Phagemid Phage Display Semi-synthetic scFv >1.0×1011
HuFabL-4 pIII-fusion, Phagemid Phage Display Naïve Fab 1.9×1010
HuFabssL-1 pIII-fusion, Phagemid Phage Display Naïve & synthetic Fab 1.8×1010

Find the Perfect Library for Your Target

Case Study: High-Diversity Libraries, High-Impact Outcomes

Dual-Strategy Discovery of Antibodies Targeting Linear Epitopes and Native Conformations of a Transmembrane Regulator
Objective In neuro-immunology and oncology research, targeting specific functional domains of transmembrane proteins is essential for deciphering intracellular signaling. This project aimed to discover high-affinity human scFv antibodies against a Type I transmembrane protein (Target X). The client required antibodies with three distinct binding profiles:
  • Specific recognition of a functional linear peptide (residues located in the just a membrane intracellular domain).
  • Specific recognition of the full-length extracellular/native protein.
  • Cross-reactive binders capable of recognizing both the synthetic peptide and the recombinant protein.
Our Strategy Leveraging our high-diversity Premade Human scFv Library, we implemented a multi-track selection strategy:
  • Track A (Peptide-Specific)
Direct biopanning against the synthetic 41-aa peptide to capture binders against the linear functional motif.
  • Track B (Protein-Specific)
Panning against the recombinant full-length protein to capture conformational epitopes.
  • Track C (Cross-Reactive Discovery)
To isolate rare clones that bridge the gap between the peptide and the native protein, we utilized an intersectional screening approach. We harvested the output from the intermediate rounds of the peptide-panning track and performed 1-2 additional rounds of cross-panning against the recombinant protein. This enforced selection pressure on clones that recognize the sequence in both its linear and folded states.
Results & Validation Successful Enrichment & Specificity
  • Successfully isolated multiple unique clones with high specificity for the synthetic fragment, ideal for biochemical assays involving the intracellular domain.
  • Identified several candidates with potent binding to the native protein, suitable for live-cell applications.
Fig.9 Graph displaying the phage ELISA validation results. (Creative Biolabs Original) Fig.10 Graph displaying the specificity validation results. (Creative Biolabs Original)
Figure 1. Specificity Profiling of Monoclonal Leads from Parallel Selection Tracks. Monoclonal Phage ELISA identified five unique clones from each screening track (synthetic peptide vs. recombinant protein) that exhibit exclusive binding to their respective selection targets with zero cross-reactivity to the alternative antigen format. Figure 2. Functional Validation of Soluble scFv Binders Against Native Epitopes. Binding assays of small-scale expressed antibodies confirm their high-affinity recognition of the full-length Target X protein. These leads are conformation-sensitive, as evidenced by their lack of reactivity toward the linear synthetic 41-aa peptide.
Identification of Cross-Reactive Leads
Through intersectional screening, we achieved significant enrichment of dual-binding candidates.
  • Phage ELISA Validation
After 1-2 rounds of cross-selection, Monoclonal Phage ELISA confirmed the isolation of clones that exhibited robust binding signals to both the synthetic 41-aa peptide and the recombinant full-length protein.
  • Sequence Delivery
Verified unique sequences were delivered to the client, providing versatile tools for both ELISA-based protein detection and peptide-based mechanistic studies.
Fig.11 Graph illustrating the library screening outcomes. (Creative Biolabs Original)
Figure 1. Enrichment Analysis of Cross-Reactive Antibody Pools. Polyclonal Phage ELISA confirmed significant enrichment of the antibody pool against both the synthetic 41-aa peptide and the full-length Target X protein following two rounds of intersectional biopanning.
Technical Highlights & Support
Strategic Flexibility
Our ability to switch antigens between selection rounds allowed for the successful "trapping" of rare cross-reactive antibodies that are often lost in standard panning. 		End-to-End Characterization
We provided the client with detailed binding kinetics and sequence analysis, ensuring the leads were ready for downstream format conversion (e.g., scFv-to-IgG).

Share Your Target Details. Get Pricing.

Related Services

Find additional antibody discovery services tailored to your specific needs.

Fig.15 Bi-functional antibody discovery. (Creative Biolabs AI)

Bi-functional Antibody Discovery

Fig.13 Anti-peptide/protein antibody discovery. (Creative Biolabs AI)

Anti-Peptide/Protein Antibody Discovery

Fig.12 Functional human antibody discovery. (Creative Biolabs AI)

Functional Human Antibody Discovery

Fig.14 Anti-Cell-based target antibody discovery. (Creative Biolabs AI)

Anti-Cell-based Target Antibody Discovery

Fig.16 Cell-internalizing antibody discovery. (Creative Biolabs AI)

Cell-Internalizing Antibody Discovery

Fig.17 Anti-epitope antibody discovery. (Creative Biolabs AI)

Anti-Epitope Antibody Discovery

Fig.18 Antibody discovery for immunotherapy. (Creative Biolabs AI)

Antibody Discovery for Immunotherapy

Why Choose Us?

Library–Screening Synergy

Our 1e10-1e11 diversity libraries plus multi-parameter panning yield diverse, high-specificity binders primed for function not just affinity.

Functional-First Decisions

Integrated cell-based assays and epitope binning ensure MoA-relevant leads that translate in vivo.

Radical Transparency

End-to-end data access (including NGS clustering and rank lists) enables confident, audit-ready decisions.

QA-Backed Rigor

Reproducible biophysical panels and standardized frameworks improve stability and manufacturability from day one.

Weeks, Not Months

Streamlined enrichment-to-IgG conversion pipelines compress hit-to-lead timelines without sacrificing rigor.

Inquiry & Contact

At Creative Biolabs, we specialize in transforming your antibody discovery needs into actionable, high-quality leads. We invite you to connect with our experts to design a custom strategy based on your target and discovery goals.

Please include the following details in your inquiry:

FAQ

  1. What therapeutic areas can be addressed by your Premade Antibody Libraries?

    Our libraries are designed with high genetic diversity and structural stability, making them suitable for virtually any disease-specific target, including:
    Oncology: Tumor-associated antigens (TAAs) and checkpoint inhibitors.
    Infectious Diseases: Viral surface proteins, bacterial toxins, and conserved epitopes.
    Autoimmune & Inflammatory Diseases: Pro-inflammatory cytokines and cell surface receptors.
    Neurodegenerative Diseases: Aggregated proteins (e.g., Amyloid-beta) and blood-brain barrier (BBB) shuttles.

  2. Why choose a Premade Library over a custom Immunized Library for my target?

    The primary advantage is speed and versatility. Instant Access: Skip the 3-5 months animal immunization and library construction phase. No Immune Tolerance: Unlike animals, our in vitro selection platforms can identify antibodies against highly conserved human proteins or "self-antigens" that are typically non-immunogenic. Controlled Environment: We can fine-tune screening conditions (pH, salt concentration, or presence of inhibitors) to mimic specific disease microenvironments.

  3. How do you handle "undruggable" or complex disease targets?

    We specialize in challenging targets such as GPCRs, Ion Channels, and Multi-pass Transmembrane Proteins. By leveraging our Yeast Display platform, we can perform FACS-based sorting using cells that naturally express the target in its native conformation, ensuring the discovered antibodies are functional in a biological context.

  4. Can the antibodies be optimized for specific delivery formats (e.g., ADC, CAR-T, or Bi-specifics)?

    Yes. Our discovery pipeline is format-agnostic. Once a high-affinity binder is identified from the scFv or Fab library, we can engineer it into: ADC/RDC: Internalizing antibodies with optimized cysteine residues for conjugation. CAR-T/NK: High-stability scFvs with validated binding kinetics. Bi-specifics/Multi-specifics: Frameworks compatible with various "knobs-into-holes".


All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Related Sections
Online Inquiry
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2026 Creative Biolabs. | Contact Us